ES2143553T3 - Anticuerpos anti-gp39 y sus utilizaciones. - Google Patents

Anticuerpos anti-gp39 y sus utilizaciones.

Info

Publication number
ES2143553T3
ES2143553T3 ES94926659T ES94926659T ES2143553T3 ES 2143553 T3 ES2143553 T3 ES 2143553T3 ES 94926659 T ES94926659 T ES 94926659T ES 94926659 T ES94926659 T ES 94926659T ES 2143553 T3 ES2143553 T3 ES 2143553T3
Authority
ES
Spain
Prior art keywords
cell
receptor
antigen
methods
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94926659T
Other languages
English (en)
Inventor
Randolph J Noelle
Teresa M Foy
Alejandro Aruffo
Jeffrey A Ledbetter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dartmouth College
Bristol Myers Squibb Pharmaceutical Research Institute
Bristol Myers Squibb Pharma Co
Original Assignee
Dartmouth College
Bristol Myers Squibb Pharmaceutical Research Institute
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26814047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2143553(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/232,929 external-priority patent/US5869049A/en
Application filed by Dartmouth College, Bristol Myers Squibb Pharmaceutical Research Institute, Bristol Myers Squibb Pharma Co filed Critical Dartmouth College
Application granted granted Critical
Publication of ES2143553T3 publication Critical patent/ES2143553T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE EXPONEN ANTICUERPOS QUE SE FIJAN A UNA PROTEINA GP39 (TAMBIEN REFERIDA COMO LIGANDO CD40). PREFERIBLEMENTE, LOS ANTICUERPOS SON ANTICUERPOS MONOCLONALES DE UN ISOTIPO IGG1 Y SE FIJAN A LA GP39. EN UNA INCORPORACION PREFERIDA, UN ANTICUERPO DE LA INVENCION SE FIJA A UN EPITOPO RECONOCIDO POR UN ANTICUERPO MONOCLONAL 24-31, PRODUCIDO POR UN HIBRIDOMA 24-31 (ATCC NUMERO DE ACCESO...) O SE FIJA A UN EPITOPO RECONOCIDO POR UN ANTICUERPO MONOCLONAL 89-76 (ATCC NUMERO DE ACCESO...). TAMBIEN SE EXPONEN COMPOSICIONES FARMACEUTICAS QUE CONTIENEN LOS ANTICUERPOS. LOS ANTICUERPOS DE LA INVENCION SON UTILES PARA INHIBIR LA PROLIFERACION Y DIFERENCIACION DE LA CELULA B, LAS RESPUESTAS DE LA CELULA T Y PARA INDUCIR LA TOLERANCIA A LA CELULA T. LAS MOLECULAS DE ACIDO NUCLEICO QUE CODIFICAN LOS ANTICUERPOS ANTIGP39, O PARTES DE LOS MISMOS, ADEMAS DE VECTORES DE EXPRESION Y CELULAS ANFITRIONES QUE INCORPORAN DICHAS MOLECULAS DE ACIDO NUCLEICO TAMBIEN SE ENCUENTRAN EN LA INVENCION.
ES94926659T 1993-09-02 1994-09-02 Anticuerpos anti-gp39 y sus utilizaciones. Expired - Lifetime ES2143553T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11625593A 1993-09-02 1993-09-02
US08/232,929 US5869049A (en) 1993-09-02 1994-04-25 Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists

Publications (1)

Publication Number Publication Date
ES2143553T3 true ES2143553T3 (es) 2000-05-16

Family

ID=26814047

Family Applications (2)

Application Number Title Priority Date Filing Date
ES94926659T Expired - Lifetime ES2143553T3 (es) 1993-09-02 1994-09-02 Anticuerpos anti-gp39 y sus utilizaciones.
ES94926677T Expired - Lifetime ES2120067T3 (es) 1993-09-02 1994-09-02 Metodos para inducir tolerancia de celulas t antigeno especifica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES94926677T Expired - Lifetime ES2120067T3 (es) 1993-09-02 1994-09-02 Metodos para inducir tolerancia de celulas t antigeno especifica.

Country Status (17)

Country Link
US (5) US5747037A (es)
EP (2) EP0721469B1 (es)
JP (3) JP3007977B2 (es)
CN (2) CN1127351C (es)
AT (2) ATE188487T1 (es)
AU (2) AU696235B2 (es)
DE (2) DE69422523T2 (es)
DK (2) DK0721469T3 (es)
ES (2) ES2143553T3 (es)
FI (2) FI105528B (es)
GR (2) GR3027658T3 (es)
HU (2) HU220296B (es)
IL (1) IL110855A (es)
NO (2) NO321036B1 (es)
NZ (3) NZ273221A (es)
PT (1) PT721469E (es)
WO (2) WO1995006666A1 (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
AU696235B2 (en) * 1993-09-02 1998-09-03 Bristol-Myers Squibb Company Anti-GP39 antibodies and uses therefor
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
JPH08239324A (ja) * 1995-03-03 1996-09-17 Fusanori Hamashima 免疫抑制剤
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US5916560A (en) * 1996-03-20 1999-06-29 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith
DE19634159C1 (de) * 1996-08-23 1997-09-25 Gsf Forschungszentrum Umwelt Induktion einer Tumorimmunität durch Injektion von Hybridzellen
WO1998008541A1 (en) * 1996-08-30 1998-03-05 Genzyme Corporation Inhibition of primary and/or secondary immune response to repeat adenoviral vector administration using cd40l specific antibodies
BR9807471A (pt) * 1997-01-10 2000-03-21 Biogen Inc Uso do composto anti-cd40l
US6428782B1 (en) * 1997-05-23 2002-08-06 Hadasit Medical Research Services And Development Ltd. Non-myeloablative tolerogenic treatment
US7553487B2 (en) * 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
ES2277460T3 (es) 1998-12-14 2007-07-01 Genetics Institute, Llc Cadena del receptor de la citoquina.
WO2000038708A1 (en) * 1998-12-24 2000-07-06 Phairson Medical Inc. Treatment and prevention of immune rejection reactions
WO2000072882A1 (fr) * 1999-06-01 2000-12-07 Eisai Co., Ltd. Agents prophylactiques du purpura thrombocytopenique idiopathique
WO2001000679A2 (en) * 1999-06-29 2001-01-04 University Of Massachusetts Methods for inducing t cell non-responsiveness to a tissue or organ graft
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
EP1262194A4 (en) * 2000-03-06 2003-05-07 Eisai Co Ltd HEALING AND PREVENTIVE AGENTS FOR THE ANTIPHOSPHOLIPID-ANTIBODY SYNDROME
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
JP2003531178A (ja) * 2000-04-25 2003-10-21 アイデック ファーマスーティカルズ コーポレイション 中枢神経系リンパ腫治療用のリツキシマブのクモ膜下投与
AU2001261585B2 (en) 2000-05-12 2006-08-31 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
AU7522401A (en) * 2000-06-06 2001-12-17 Idec Pharma Corp Non-agonistic antibodies to human gp39, compositions containing, and therapeuticuse thereof
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
BR0112104A (pt) 2000-07-03 2004-07-20 Bristol Myers Squibb Co Processos para tratamento de doenças reumáticas usando uma molécula de ctla4 solúvel
WO2002040050A1 (en) * 2000-11-14 2002-05-23 The University Of Louisville Research Foundation, Inc. Non-lethal methods for conditioning a recipient for bone marrow transplantation
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
ATE390931T1 (de) 2001-05-23 2008-04-15 Bristol Myers Squibb Co Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
WO2003086463A1 (fr) * 2002-04-03 2003-10-23 Keio University Remedes contre le pemphigus, contenant un antagoniste du cd40l comme principe actif
EP2366718A3 (en) * 2002-06-28 2012-05-02 Domantis Limited Ligand
CN1326878C (zh) * 2003-04-29 2007-07-18 中国抗体制药有限公司 抗人非何杰金淋巴瘤嵌合抗体及其衍生物与应用
JP4667383B2 (ja) * 2003-06-13 2011-04-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド アグリコシル抗ｃｄ１５４（ｃｄ４０リガンド）抗体およびその使用
AU2011224032B2 (en) * 2003-06-13 2013-01-31 Biogen Ma Inc. Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
ES2533084T3 (es) * 2003-12-23 2015-04-07 Genentech, Inc. Tratamiento del cáncer con anticuerpos monoclonales anti-IL 13 novedosos
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
RS20070027A (en) 2004-07-26 2008-11-28 Biogen Idec Ma Inc., Anti-cd154 antibodies
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
EP1851308B1 (en) * 2005-02-02 2013-08-21 NewSouth Innovations Pty Limited Cd4+ cd25+ t-cells activated to a specific antigen
CN100423775C (zh) * 2005-04-15 2008-10-08 中国农业科学院兰州兽医研究所 牛衣原体病灭活疫苗及其制备与检验方法
PT1889065E (pt) 2005-05-18 2013-09-27 Novartis Ag Métodos para o diagnóstico e tratamento de doenças tendo uma componente autoimune e/ou inflamatória
PT2298815E (pt) * 2005-07-25 2015-07-16 Emergent Product Dev Seattle Moléculas de ligaçao especificas para cd37 e especificas para cd20
EP1996716B1 (en) * 2006-03-20 2011-05-11 The Regents of the University of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
CA3149553C (en) * 2006-06-12 2023-11-21 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
US8569059B2 (en) 2006-08-02 2013-10-29 Newsouth Innovations Pty Limited Method of identifying CD4+ CD25+ T-cells activated to an antigen which express CD8
CA2685123A1 (en) * 2007-04-23 2008-10-30 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
WO2009032949A2 (en) 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
DE102008044687A1 (de) 2007-10-27 2009-04-30 Joint Solar Silicon Gmbh & Co. Kg Aufbereitung von Formlingen aus Reinstsilizium
CA2719924C (en) * 2008-04-11 2017-10-03 Philip Tan Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
US8911739B2 (en) 2009-02-10 2014-12-16 Trustees Of Columbia University In The City Of New York Methods of preventing rejection of transplanted tissue by administering anti-CD40L antibody and dendritic cells loaded with Hsp60sp peptide
CN102770457A (zh) * 2009-03-10 2012-11-07 贝勒研究院 靶向抗原呈递细胞的疫苗
WO2013013708A1 (en) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Treatment of acute rejection in renal transplant
NZ756750A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
JP6546178B2 (ja) 2013-09-13 2019-07-17 ジェネンテック， インコーポレイテッド 細胞株中の宿主細胞タンパク質及び組換えポリペプチド産物を検出及び定量化するための組成物並びに方法
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
JP6826113B2 (ja) 2015-07-14 2021-02-03 イミューネクスト・インコーポレイテッド 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用
JP7049988B2 (ja) 2015-08-05 2022-04-07 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ１５４抗体及びこれを使用する方法
UA126278C2 (uk) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Поліпептиди, які зв'язують cd3
CA2946465C (en) 2015-11-12 2022-03-29 Delta Faucet Company Ozone generator for a faucet
RU2022108410A (ru) 2017-05-24 2022-04-05 ЭйЭлЭс ТЕРАПИ ДЕВЕЛОПМЕНТ ИНСТИТЬЮТ Терапевтические антитела против лиганда cd40
KR102142499B1 (ko) * 2019-09-11 2020-08-10 재단법인 오송첨단의료산업진흥재단 Ykl-40 표적 인간 단일클론항체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5645820A (en) * 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
AU661360B2 (en) * 1991-10-25 1995-07-20 Immunex Corporation Novel cytokine
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
AU5098493A (en) * 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5597563A (en) * 1992-09-04 1997-01-28 Beschorner; William E. Method induction of antigen-specific immune tolerance
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
AU696235B2 (en) * 1993-09-02 1998-09-03 Bristol-Myers Squibb Company Anti-GP39 antibodies and uses therefor
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40

Also Published As

Publication number Publication date
AU678532B2 (en) 1997-05-29
HUT74250A (en) 1996-11-28
AU7642994A (en) 1995-03-22
HU220296B (hu) 2001-11-28
AU7644594A (en) 1995-03-22
EP0721469A1 (en) 1996-07-17
CN100341896C (zh) 2007-10-10
CN1149299A (zh) 1997-05-07
WO1995006481A1 (en) 1995-03-09
ES2120067T3 (es) 1998-10-16
EP0721346A1 (en) 1996-07-17
US5876718A (en) 1999-03-02
EP0721346B1 (en) 1998-06-10
JP2991499B2 (ja) 1999-12-20
JPH09502096A (ja) 1997-03-04
AU707110B2 (en) 1999-07-01
US5747037A (en) 1998-05-05
GR3033095T3 (en) 2000-08-31
AU3518397A (en) 1997-10-30
DE69411025T2 (de) 1999-01-07
IL110855A0 (en) 1994-11-28
JP3098739B2 (ja) 2000-10-16
NO321036B1 (no) 2006-03-06
ATE167062T1 (de) 1998-06-15
DE69422523D1 (de) 2000-02-10
CN1127351C (zh) 2003-11-12
JPH11189543A (ja) 1999-07-13
AU696235B2 (en) 1998-09-03
GR3027658T3 (en) 1998-11-30
NO960861L (no) 1996-04-30
FI106306B (fi) 2001-01-15
WO1995006666A1 (en) 1995-03-09
JP3007977B2 (ja) 2000-02-14
ATE188487T1 (de) 2000-01-15
DK0721346T3 (da) 1999-03-22
FI960980A0 (fi) 1996-03-01
NO321098B1 (no) 2006-03-20
NO960862L (no) 1996-04-30
NZ549136A (en) 2008-02-29
US6312692B1 (en) 2001-11-06
DE69422523T2 (de) 2000-10-12
DE69411025D1 (de) 1998-07-16
FI960978A0 (fi) 1996-03-01
HUT74246A (en) 1996-11-28
NZ273207A (en) 1997-09-22
NO960862D0 (no) 1996-03-01
NZ273221A (en) 2001-09-28
PT721469E (pt) 2000-04-28
EP0721469B1 (en) 2000-01-05
FI960978A (fi) 1996-04-29
HU9600522D0 (en) 1996-04-29
US7722874B2 (en) 2010-05-25
NO960861D0 (no) 1996-03-01
JPH09502186A (ja) 1997-03-04
CN1134113A (zh) 1996-10-23
FI960980A (fi) 1996-04-30
IL110855A (en) 1999-04-11
FI105528B (fi) 2000-09-15
US20060222649A1 (en) 2006-10-05
DK0721469T3 (da) 2000-05-01
HU9600521D0 (en) 1996-04-29
US20020187135A1 (en) 2002-12-12
HU218610B (hu) 2000-10-28

Similar Documents

Publication Publication Date Title
ES2143553T3 (es) Anticuerpos anti-gp39 y sus utilizaciones.
Londei et al. Persistence of collagen type II-specific T-cell clones in the synovial membrane of a patient with rheumatoid arthritis.
Rosa et al. Bone marrow CD8 T cells are in a different activation state than those in lymphoid periphery
DK0941478T3 (da) Assaymetode for peptidspecifikke T-celler
Merville et al. Detection of single cells secreting IFN-gamma, IL-6, and IL-10 in irreversibly rejected human kidney allografts, and their modulation by IL-2 and IL-4
CA2194239A1 (en) Methods for modulating t cell responses by manipulating a common cytokine receptor gamma chain
TW272197B (es)
van der Melde et al. Enumeration of lymphokine‐secreting cells as a quantitative measure for cellular immune responses in rhesus macaques
DK0728016T3 (da) Anvendelse af anti-idiotypiske antistoffer til forebyggelse af hyperakut afstødning af xenotransplantater
ATE403867T1 (de) Evaluierung adjuvanshaltiger impfstoffe
AP2368A (en) Novel expression vectors and uses thereof.
van Essen et al. Role of B cells in maintaining helper T–cell memory
Roehm et al. Helper signals in B lymphocyte differentiation
Süss et al. Identification of T-Cell Epitopes
Mitchison Epitope Linkage in the Immune Response and Its Implications for Lymphoid Architecture and Immunological Memory
MX9605051A (es) Metodos para inducir la tolerancia de celulas t a un injerto u organo.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 721469

Country of ref document: ES